TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34529341

Group type: EXPERIMENTAL
Intervention: Oral minoxidil 0.25 mg tablets
Number of subjects: 72

Group type: COMPARATOR
Intervention: Topical minoxidil 2% solution
Number of subjects: 72
Study: 36272010

Group type: EXPERIMENTAL
Intervention: Auto-cleaning device (Y-brush®) for 5 seconds per jaw
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual toothbrush for a freely chosen time up to 4 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Auto-cleaning device (Y-brush®) for 15 seconds per jaw
Number of subjects: 20
Study: 33958795

Group type: EXPERIMENTAL
Intervention: AI-enabled ECG results
Number of subjects: 22641

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 22641
Study: 34261879

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 63
Study: 34787858

Group type: EXPERIMENTAL
Intervention: PICC chemotherapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Routine intravenous injection
Number of subjects: 150
Study: 32098534

Group type: EXPERIMENTAL
Intervention: Vitamin E blended HXLPE
Number of subjects: 199

Group type: COMPARATOR
Intervention: UHMWPE
Number of subjects: 199
Study: 33012017

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (laser application twice a week, totaling 8 sessions, and gel placebo for 30 consecutive days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Topical clobetasol propionate 0.05% (application three times a day for 30 consecutive days with laser placebo applied twice a week)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Photobiomodulation and topical clobetasol 0.05%
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Number of subjects: 34
Study: 33248743

Group type: EXPERIMENTAL
Intervention: Training clinicians to increase TUD treatment
Number of subjects: 182

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 182
Study: 34253180

Group type: EXPERIMENTAL
Intervention: Cognitive impairment assessment
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Functional impairment assessment
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Frailty assessment
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Care level assignment
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Geriatric diagnosis prevalence
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Dementia diagnosis prevalence
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Depression symptom prevalence
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Medication usage
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Health care service utilization
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Care related needs assessment
Number of subjects: 402
Study: 35457632

Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity program (twice a week for 8 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 34010843

Group type: EXPERIMENTAL
Intervention: Mirabegron (50 mg once daily)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Solifenacin (5 mg)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 32829925

Group type: EXPERIMENTAL
Intervention: Group PM (patients who listened to music before the operation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group PM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group CM (patients who listened to music both before and during the operation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group CM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group NM (Non‐Music, control group)
Number of subjects: 0
Study: 33347024

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (300 mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 32421444

Group type: COMPARATOR
Intervention: Standard anthracycline plus ifosfamide neoadjuvant chemotherapy (A+I)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Histology-tailored neoadjuvant chemotherapy (HT)
Number of subjects: 287
Study: 35656979

Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Number of subjects: 5390

Group type: COMPARATOR
Intervention: Acetylsalicylic Acid (Aspirin)
Number of subjects: 5390
Study: 34087823

Group type: EXPERIMENTAL
Intervention: Yoga-based cognitive behavioral therapy (Y-CBT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 58
Study: 32006002

Group type: EXPERIMENTAL
Intervention: rhGM‐CSF gel
Number of subjects: 62
Study: 36057608

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (BuNa)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 100
Study: 34464382

Group type: EXPERIMENTAL
Intervention: ctDNA clearance during nCRT
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Detection of acquired mutations in ctDNA
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: ctDNA clearance
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Risk score predictive model combining ctDNA and MRI
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: ctDNA alone
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: MRI alone
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Detection of potential CRC driver genes in ctDNA after nCRT
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Detectable driver mutations and positive HR_feature after surgery
Number of subjects: 119
Study: 32577902

Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients
Number of subjects: 81

Group type: COMPARATOR
Intervention: COVID-19 negative controls
Number of subjects: 81
Study: 36191231

Group type: EXPERIMENTAL
Intervention: Digital musical rhythm training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Word search (control)
Number of subjects: 0
Study: 33950073

Group type: EXPERIMENTAL
Intervention: Motivational interviewing associated with cognitive behavioral therapy (CBT)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Control group (CBT only)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Motivational interviewing group
Number of subjects: 329

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 329
Study: 32439819

Group type: EXPERIMENTAL
Intervention: Lower eGFR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher UACR
Number of subjects: 0
Study: 36172209

Group type: EXPERIMENTAL
Intervention: Ongoing support for the implementation of BCP-VAMOS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional didactic approach (control group)
Number of subjects: 0
Study: 32833291

Group type: EXPERIMENTAL
Intervention: Comprehend, Cope, and Connect (CCC) intervention delivered face-to-face
Number of subjects: 23
Study: 35303462

Group type: EXPERIMENTAL
Intervention: CBR plus facility-based care
Number of subjects: 166

Group type: COMPARATOR
Intervention: Facility-based care
Number of subjects: 166
Study: 32241214

Group type: EXPERIMENTAL
Intervention: Incentive group (free eye exam provided)
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Education group (free eye exam provided)
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Incentive and education group (free eye exam provided)
Number of subjects: 1454

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1454
Study: 36273490

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV booster vaccination (5 × 10^10 viral particles)
Number of subjects: 50
Study: 34302893

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) levels during chemoradiation therapy (CRT)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) levels during CRT
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) levels before treatment
Number of subjects: 225
Study: 34114429

Group type: EXPERIMENTAL
Intervention: Amantadine (100mg BD for 14 days, then 150mg BD for 7 days, and 200mg BD for 21 days)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 57
Study: 33587659

Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban regimen
Number of subjects: 21005
Study: 36191401

Group type: EXPERIMENTAL
Intervention: Anteromedial portal (AMP) technique
Number of subjects: 33

Group type: COMPARATOR
Intervention: Transtibial (TT) technique
Number of subjects: 33
Study: 33640458

Group type: EXPERIMENTAL
Intervention: External cold and vibration (Buzzy®) applied for 30 seconds before and during vaccination
Number of subjects: 90

Group type: COMPARATOR
Intervention: No intervention during vaccination
Number of subjects: 90
Study: 32250066

Group type: EXPERIMENTAL
Intervention: 1-day preparation using PEG 3350 (4 g/kg/day) + bisacodyl
Number of subjects: 72

Group type: COMPARATOR
Intervention: 2-day preparation using PEG 3350 (2 g/kg/day) + bisacodyl
Number of subjects: 72
Study: 35554590

Group type: EXPERIMENTAL
Intervention: Suvorexant (initially 10 mg, increased to 20 mg after 1 week if tolerated)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 33226002

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 1596

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 1596
Study: 34511307

Group type: COMPARATOR
Intervention: Single vision contact lenses
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low add multifocal soft contact lenses
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High add multifocal soft contact lenses
Number of subjects: 24
Study: 33793700

Group type: COMPARATOR
Intervention: Hysterosalpingography (HSG)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Hysterosalpingo-contrast ultrasonography (HyCoUs)
Number of subjects: 56
Study: 35880283

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Simple acupuncture
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (routine treatment)
Number of subjects: 150
Study: 34014982

Group type: EXPERIMENTAL
Intervention: Dual active-ingredient long-lasting insecticidal nets (LLINs) combining chlorfenapyr or pyriproxifen with alpha-cypermethrin
Number of subjects: 10807

Group type: COMPARATOR
Intervention: Standard pyrethroid LLINs
Number of subjects: 10807

Group type: EXPERIMENTAL
Intervention: Alpha-cypermethrin
Number of subjects: 10807

Group type: EXPERIMENTAL
Intervention: PBO pre-exposure followed by alpha-cypermethrin
Number of subjects: 10807

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 10807
Study: 32956890

Group type: EXPERIMENTAL
Intervention: ESPB (Erector Spinae Plane Block)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: mTLIP (Modified-Thoracolumbar Interfascial Plane Block)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ESPB
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: mTLIP
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 33629239

Group type: EXPERIMENTAL
Intervention: Unisol-CV (UCV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phosphate-buffered saline (PBS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dulbecco's Modified Eagle's Medium: Nutrient Mixture F-12 (DMEM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: X-VIVO
Number of subjects: 0
Study: 33675695

Group type: EXPERIMENTAL
Intervention: EDIFY interventions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care (nonintervention group)
Number of subjects: 100
Study: 35896519

Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy for insomnia (MBTI)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Sleep hygiene, education, and exercise programme (SHEEP)
Number of subjects: 113
Study: 33691304

Group type: EXPERIMENTAL
Intervention: Known diabetes
Number of subjects: 9013

Group type: EXPERIMENTAL
Intervention: New diabetes
Number of subjects: 9013

Group type: COMPARATOR
Intervention: BMS or DES
Number of subjects: 9013
Study: 32745945

Group type: EXPERIMENTAL
Intervention: Loss condition of the computerized task
Number of subjects: 364

Group type: COMPARATOR
Intervention: Control condition of the computerized task
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Craving
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Alcohol misuse
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Gambling severity
Number of subjects: 364
Study: 32223585

Group type: EXPERIMENTAL
Intervention: Fascial therapy (three 45‐min sessions over a 3‐week period)
Number of subjects: 14
Study: 34030720

Group type: EXPERIMENTAL
Intervention: Exoskeleton-assisted walking (EAW)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 18
Study: 32813935

Group type: EXPERIMENTAL
Intervention: Intracameral epinephrine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 30
Study: 35132871

Group type: EXPERIMENTAL
Intervention: High baseline neutrophil-lymphocyte ratio (NLR; ≥3.8)
Number of subjects: 756
Study: 33276518

Group type: EXPERIMENTAL
Intervention: Oral resveratrol supplementation for 4 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo supplementation for 4 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral resveratrol supplementation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 9
Study: 34097301

Group type: EXPERIMENTAL
Intervention: Stay Active at Home (SAaH) reablement training program for homecare staff
Number of subjects: 264

Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 264
Study: 33032338

Group type: EXPERIMENTAL
Intervention: Amplitude panning
Number of subjects: 27

Group type: COMPARATOR
Intervention: Physical sources
Number of subjects: 27

Group type: COMPARATOR
Intervention: Panned sources
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall localization task
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Total and elevation errors
Number of subjects: 27
Study: 35977462

Group type: EXPERIMENTAL
Intervention: Sotrovimab (monoclonal antibody for SARS-CoV-2 infection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34008769

Group type: EXPERIMENTAL
Intervention: Isotonic exercises for pain relief
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no isotonic exercises)
Number of subjects: 23
Study: 35618959

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall survival (OS)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting OS
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 280
Study: 34285713

Group type: EXPERIMENTAL
Intervention: COC with GR blockade (mifepristone; 80.0 mg/kg; po)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: COC with MR blockade (spironolactone; 0.25 mg/kg; po)
Number of subjects: 24

Group type: COMPARATOR
Intervention: COC (1.0 μg ethinylestradiol and 5.0 μg levonorgestrel; po)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vehicle (po)
Number of subjects: 24
Study: 35101832

Group type: EXPERIMENTAL
Intervention: Bacillus clausii UBBC07 (oral suspension of 2 billion spores twice daily for 30 days)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (standard treatment)
Number of subjects: 46
Study: 34838105

Group type: EXPERIMENTAL
Intervention: SPIN-SELF Program (group-based intervention delivery format)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 33025883

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (DC)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (CC)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (DC) in hyperuricaemic participants
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (CC) in non-hyperuricaemic participants
Number of subjects: 51
Study: 36251165

Group type: EXPERIMENTAL
Intervention: Rencofilstat (RCF) 225-mg soft gelatin capsules with high-fat meal
Number of subjects: 44

Group type: COMPARATOR
Intervention: Rencofilstat (RCF) 225-mg soft gelatin capsules in fasted condition
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 44

Group type: COMPARATOR
Intervention: Fasted group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High-fat meal group
Number of subjects: 44
Study: 32543929

Group type: EXPERIMENTAL
Intervention: PA + C group (MoVo‐work intervention with psychological coaching and PA component)
Number of subjects: 213
Study: 36093397

Group type: EXPERIMENTAL
Intervention: 12 weeks of core stability training, 3 times/week
Number of subjects: 31

Group type: COMPARATOR
Intervention: AIS group (no intervention)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normal group (no intervention)
Number of subjects: 31
Study: 34389569

Group type: EXPERIMENTAL
Intervention: Remote photoplethysmography imaging (rPPG) system measurements of heart rate (HR), respiratory rate (RR), and oxygen saturation (SpO 2)
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Standard acquisition system measurements of heart rate (HR), respiratory rate (RR), and oxygen saturation (SpO 2)
Number of subjects: 1045
Study: 32415365

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (IV‐TXA) 1 g before incision and 3 h later
Number of subjects: 122

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (IV‐TXA)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: IV‐TXA (meta-analysis)
Number of subjects: 122
Study: 34022863

Group type: EXPERIMENTAL
Intervention: Non-opioid postoperative protocol (standardized non-opioid analgesic prescription, limited rescue opioid prescription, patient education infographic)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Current standard of care (treating surgeons’ pre-trial postoperative analgesic regimen)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Non-opioid postoperative protocol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Current standard of care
Number of subjects: 200
Study: 32808504

Group type: EXPERIMENTAL
Intervention: Primary debulking surgery (PDS) followed by 6 cycles of standard adjuvant chemotherapy
Number of subjects: 456

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy followed by interval debulking surgery (NACT‐IDS) with 3 cycles of NACT and subsequently 3 cycles of adjuvant chemotherapy
Number of subjects: 456
Study: 35485864

Group type: EXPERIMENTAL
Intervention: 18F‐fludarabine (18F‐FLUDA) PET/CT
Number of subjects: 31

Group type: COMPARATOR
Intervention: 11C‐MET
Number of subjects: 31
Study: 33667227

Group type: EXPERIMENTAL
Intervention: Testosterone (0.5 mg) + Sildenafil (50 mg)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Testosterone (0.5 mg) + Buspirone (10 mg)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Matching Placebos
Number of subjects: 129
Study: 32991207

Group type: EXPERIMENTAL
Intervention: Aquatic Therapy Group (ATG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional Training Group (CTG)
Number of subjects: 20
Study: 34049943

Group type: EXPERIMENTAL
Intervention: Tezepelumab (700 mg intravenously at 4-week intervals for 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (intravenously at 4-week intervals for 12 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 33112025

Group type: EXPERIMENTAL
Intervention: Eversion group (n = 52)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Retraction group (n = 52)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study: 33129156

Group type: EXPERIMENTAL
Intervention: Worrisome contemplation (n = 60)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Objective contemplation (n = 63)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Diaphragmatic breathing task (n = 62)
Number of subjects: 245
Study: 33075844

Group type: EXPERIMENTAL
Intervention: 81-mg daily aspirin
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1228
Study: 33959770

Group type: EXPERIMENTAL
Intervention: Single response assessment
Number of subjects: 79

Group type: COMPARATOR
Intervention: International Myeloma Working Group criteria
Number of subjects: 79
Study: 33990483

Group type: EXPERIMENTAL
Intervention: Tree Pose‐added exercise group (30‐min conventional exercise + 2‐min Tree Pose/d for 12 wks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conservative exercise group (30 mins/d for 12 wks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tree Pose‐added exercise group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conservative exercise group
Number of subjects: 32
Study: 34511166

Group type: EXPERIMENTAL
Intervention: mNGF treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional rehabilitation treatment
Number of subjects: 60
Study: 35213366

Group type: EXPERIMENTAL
Intervention: SMART4MD tablet application
Number of subjects: 345

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 345

Group type: COMPARATOR
Intervention: Combined (PwMCI and informal caregivers)
Number of subjects: 345
Study: 32539753

Group type: EXPERIMENTAL
Intervention: Variable Resistance Training (VRT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Constant Resistance Training (CRT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (Con)
Number of subjects: 36
Study: 35745107

Group type: EXPERIMENTAL
Intervention: Flaxseed lignan supplementation (secoisolariciresinol diglucoside; SDG)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 35770588

Group type: EXPERIMENTAL
Intervention: Yoga ocular exercise (20 minutes) followed by active Acu-TENS over bilateral BL 61 and BL 62 acupoints (20 minutes)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo Acu-TENS (20 minutes) following the same yoga ocular exercise protocol
Number of subjects: 80
Study: 32710457

Group type: EXPERIMENTAL
Intervention: Genotype-guided warfarin anticoagulation
Number of subjects: 507

Group type: COMPARATOR
Intervention: Control group (clinical information only)
Number of subjects: 507
Study: 34275457

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including systematic medication review
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 107